Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

497 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
IRES complexity before IFN-alpha treatment and evolution of the viral load at the early stage of treatment in peripheral blood mononuclear cells from chronic hepatitis C patients.
Thélu MA, Leroy V, Ramzan M, Dufeu-Duchesne T, Marche P, Zarski JP. Thélu MA, et al. Among authors: leroy v. J Med Virol. 2007 Mar;79(3):242-53. doi: 10.1002/jmv.20792. J Med Virol. 2007. PMID: 17245718 Clinical Trial.
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.
Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Poynard T, et al. Among authors: leroy v. Hepatology. 1996 Oct;24(4):778-89. doi: 10.1002/hep.510240405. Hepatology. 1996. PMID: 8855176
Treatment of chronic hepatitis C by interferon for longer duration than six months.
Poynard T, Leroy V, Mathurin P, Cohard M, Opolon P, Zarski JP. Poynard T, et al. Among authors: leroy v. Dig Dis Sci. 1996 Dec;41(12 Suppl):99S-102S. doi: 10.1007/BF02087883. Dig Dis Sci. 1996. PMID: 9011484 Clinical Trial.
[Should hepatitis C be screened? Risk factors of transmission of hepatitis C virus].
Zarski JP, Leroy V. Zarski JP, et al. Among authors: leroy v. Gastroenterol Clin Biol. 1997;21(1 Pt 2):S4-10. Gastroenterol Clin Biol. 1997. PMID: 9161509 Review. French. No abstract available.
Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon.
Zarski JP, Maynard-Muet M, Chousterman S, Baud M, Barnoud R, Abergel A, Bacq Y, Combis JM, Causse X, Tran A, Oberti F, Minello A, Bresson-Hadni S, Bailly F, Raabe JJ, Leroy V, Hamici L, Hicham T, Girardin MF. Zarski JP, et al. Among authors: leroy v. Hepatology. 1998 Mar;27(3):862-7. doi: 10.1002/hep.510270332. Hepatology. 1998. PMID: 9500719 Clinical Trial.
Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C.
Leroy V, Baud M, de Traversay C, Maynard-Muet M, Lebon P, Zarski JP. Leroy V, et al. J Hepatol. 1998 Mar;28(3):375-81. doi: 10.1016/s0168-8278(98)80309-7. J Hepatol. 1998. PMID: 9551673
[Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial].
Rolachon A, Kézachian G, Causse X, Baud M, Leroy V, Maynard-Muet M, Pasquier D, Zarski JP. Rolachon A, et al. Among authors: leroy v. Gastroenterol Clin Biol. 1997;21(12):924-8. Gastroenterol Clin Biol. 1997. PMID: 9587555 Clinical Trial. French.
Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C.
Leroy V, Arvieux J, Jacob MC, Maynard-Muet M, Baud M, Zarski JP. Leroy V, et al. Br J Haematol. 1998 Jun;101(3):468-74. doi: 10.1046/j.1365-2141.1998.00722.x. Br J Haematol. 1998. PMID: 9633888
[Acute viral hepatitis A, B, C, D and E: epidemiology, etiology, diagnosis, course, prevention].
Zarski JP, Leroy V, Maynard-Muet M. Zarski JP, et al. Among authors: leroy v. Rev Prat. 1998 Sep 15;48(14):1609-14. Rev Prat. 1998. PMID: 9814059 Review. French. No abstract available.
Counselling patients with hepatitis C.
Zarski JP, Leroy V. Zarski JP, et al. Among authors: leroy v. J Hepatol. 1999;31 Suppl 1:136-40. doi: 10.1016/s0168-8278(99)80390-0. J Hepatol. 1999. PMID: 10622576 Review.
497 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback